Regulatory, legal and policy aspects

Workpackage #8

Regulatory, legal and policy aspects

iCARE4CVD’s vision to pave the way to better care for individuals with
CVD could not be realised without careful insight into the regulatory, legal,
reimbursement, and policy landscape relevant to CVD. By defining a
roadmap, framework, and a strategy for biomarker and medical AI
developments that is safe, ethical, and successful, WP8 will aim to
facilitate a successful adaption and implementation of iCARE4CVD’s
medical tools.

Meet our team

Kirsten Budig

Novo Nordisk

Kirsten Budig

Senior Public Affairs Manager
Read more

TNO

Robin Mischa van Stokkum

Researcher Digital Health and Coordinator TNO Health & Work AI Lab
Read more

Scientific Institute for Health Economics and Health Systems Research

Ines Weinhold

Managing Director at WIG2
Read more

WIG2

Rebekka Mumm

Head of Health Economics
Read more

WIG2

Franziska Theile

Research Associate
Read more

TNO

Gabriela Bodea, MA

Dutch Organisation for Applied Research
Read more
Get updated

Our related news

Read more

13 October, 2026

Can the way patients use home monitoring tell us something about their heart health? – new iCARE4CVD study

Can the way patients use home monitoring reveal something about their heart..
Read more

6 October, 2026

iCARE4CVD featured in Open Access Government

How can we turn complex cardiovascular data into better, more personalised care?..
Read more

15 September, 2026

Building Bridges: How Public-Private Collaboration Can Help Reshape Cardiovascular Innovation

Personalised cardiovascular medicine promises to give the right care to the right..
Read more

Subscribe to our newsletter

Subscribe to our newsletter to stay up to date with all the most recent information about iCARE4CVD.

Funding acknowledgment

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) and Breakthrough T1D under grant agreement No 101112022. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Vaccines Europe, EuropaBio and MedTech Europe.

Disclaimer

Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

Quick Links